S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
Log in
NASDAQ:KZR

Kezar Life Sciences Stock Forecast, Price & News

$5.83
+0.23 (+4.11 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.33
Now: $5.83
$5.92
50-Day Range
$5.27
MA: $5.68
$6.99
52-Week Range
$2.18
Now: $5.83
$9.79
Volume237,700 shs
Average Volume219,591 shs
Market Capitalization$269.74 million
P/E RatioN/A
Dividend YieldN/A
Beta0.33
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials across five autoimmune indications, including lupus nephritis, autoimmune hemolytic anemia, immune thrombocytopenia, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-616, a selective immunoproteasome inhibitor for the treatment of various autoimmune disease indications; and KZR-TBD for the treatment of oncology and autoimmunity. The company was founded in 2015 and is headquartered in South San Francisco, California.
Kezar Life Sciences logo

Headlines

Kezar Life Sciences Added to the Nasdaq Biotechnology Index
December 14, 2020 |  finance.yahoo.com
Is KZR A Good Stock To Buy Now?
December 14, 2020 |  finance.yahoo.com
Kezar Life Sciences: Keyed In On Autoimmune Therapies
November 8, 2020 |  seekingalpha.com
Kezar Life Sciences EPS misses by $0.02
November 5, 2020 |  seekingalpha.com
KEZAR LIFE SCIENC.DL-,001 (2KZ.MU)
October 12, 2020 |  au.finance.yahoo.com
Kezar Life Sciences Inc. Regist (2KZ.SG)
October 10, 2020 |  au.finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KZR
CUSIPN/A
CIKN/A
Phone650-822-5600
Employees40
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.08 per share

Profitability

Net Income$-35,090,000.00

Miscellaneous

Market Cap$269.74 million
Next Earnings Date3/11/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.26 out of 5 stars

Medical Sector

815th out of 1,968 stocks

Pharmaceutical Preparations Industry

391st out of 771 stocks

Analyst Opinion: 3.4Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
$5.83
+0.23 (+4.11 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KZR News and Ratings via Email

Sign-up to receive the latest news and ratings for KZR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Kezar Life Sciences (NASDAQ:KZR) Frequently Asked Questions

Is Kezar Life Sciences a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kezar Life Sciences in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Kezar Life Sciences stock.
View analyst ratings for Kezar Life Sciences
or view top-rated stocks.

What stocks does MarketBeat like better than Kezar Life Sciences?

Wall Street analysts have given Kezar Life Sciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Kezar Life Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Kezar Life Sciences?

Kezar Life Sciences saw a increase in short interest during the month of February. As of February 12th, there was short interest totaling 1,680,000 shares, an increase of 43.6% from the January 28th total of 1,170,000 shares. Based on an average daily volume of 229,900 shares, the days-to-cover ratio is presently 7.3 days.
View Kezar Life Sciences' Short Interest
.

When is Kezar Life Sciences' next earnings date?

Kezar Life Sciences is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Kezar Life Sciences
.

How were Kezar Life Sciences' earnings last quarter?

Kezar Life Sciences, Inc. (NASDAQ:KZR) posted its quarterly earnings results on Wednesday, August, 5th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.04.
View Kezar Life Sciences' earnings history
.

How has Kezar Life Sciences' stock been impacted by Coronavirus?

Kezar Life Sciences' stock was trading at $3.99 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, KZR stock has increased by 46.1% and is now trading at $5.83.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for KZR?

4 equities research analysts have issued 1 year price objectives for Kezar Life Sciences' stock. Their forecasts range from $12.00 to $18.00. On average, they expect Kezar Life Sciences' stock price to reach $15.00 in the next year. This suggests a possible upside of 157.3% from the stock's current price.
View analysts' price targets for Kezar Life Sciences
or view top-rated stocks among Wall Street analysts.

Who are Kezar Life Sciences' key executives?

Kezar Life Sciences' management team includes the following people:
  • Mr. John Franklin Fowler, Co-Founder, CEO & Director (Age 49, Pay $720.54k)
  • Dr. Christopher J. Kirk, Co-Founder, Pres, Chief Scientific Officer & Director (Age 49, Pay $536.59k)
  • Mr. Marc L. Belsky, CFO & Sec. (Age 66, Pay $491.79k)
  • Dr. Jack Taunton, Co-Founder
  • Michael Wolfe, Director of Fin. & Operations
  • Ms. Vassiliki Economides, Sr. VP of Strategy & External Affairs (Age 41)
  • Dr. Noreen Roth Henig, Chief Medical Officer (Age 56)

Who are some of Kezar Life Sciences' key competitors?

What other stocks do shareholders of Kezar Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kezar Life Sciences investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Pfizer (PFE), VYNE Therapeutics (vyne), Dynavax Technologies (DVAX), Gilead Sciences (GILD), AbbVie (ABBV), Aldeyra Therapeutics (ALDX) and Exelixis (EXEL).

When did Kezar Life Sciences IPO?

(KZR) raised $70 million in an IPO on Thursday, June 21st 2018. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair acted as the underwriters for the IPO.

What is Kezar Life Sciences' stock symbol?

Kezar Life Sciences trades on the NASDAQ under the ticker symbol "KZR."

Who are Kezar Life Sciences' major shareholders?

Kezar Life Sciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.44%), Opaleye Management Inc. (1.53%), Candriam Luxembourg S.C.A. (1.26%), Alyeska Investment Group L.P. (1.26%), Alyeska Investment Group L.P. (1.26%) and Kennedy Capital Management Inc. (1.14%). Company insiders that own Kezar Life Sciences stock include Christopher J Kirk, Equal Talent Investments Ltd, Franklin M Berger, John Franklin Fowler, Marc Belsky, Middleton Angus, Morningside Venture Investment and Vassiliki Economides.
View institutional ownership trends for Kezar Life Sciences
.

Which institutional investors are selling Kezar Life Sciences stock?

KZR stock was sold by a variety of institutional investors in the last quarter, including Baker BROS. Advisors LP, CHI Advisors LLC, Victory Capital Management Inc., Candriam Luxembourg S.C.A., JPMorgan Chase & Co., Northern Trust Corp, Virtus ETF Advisers LLC, and Alyeska Investment Group L.P..
View insider buying and selling activity for Kezar Life Sciences
or view top insider-selling stocks.

Which institutional investors are buying Kezar Life Sciences stock?

KZR stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Wells Fargo & Company MN, GSA Capital Partners LLP, Caas Capital Management LP, Opaleye Management Inc., Renaissance Technologies LLC, ProShare Advisors LLC, and State of Wisconsin Investment Board. Company insiders that have bought Kezar Life Sciences stock in the last two years include Christopher J Kirk, Equal Talent Investments Ltd, Franklin M Berger, John Franklin Fowler, Marc Belsky, Middleton Angus, Morningside Venture Investment, and Vassiliki Economides.
View insider buying and selling activity for Kezar Life Sciences
or or view top insider-buying stocks.

How do I buy shares of Kezar Life Sciences?

Shares of KZR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kezar Life Sciences' stock price today?

One share of KZR stock can currently be purchased for approximately $5.83.

How much money does Kezar Life Sciences make?

Kezar Life Sciences has a market capitalization of $269.74 million. The company earns $-35,090,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis.

How many employees does Kezar Life Sciences have?

Kezar Life Sciences employs 40 workers across the globe.

What is Kezar Life Sciences' official website?

The official website for Kezar Life Sciences is www.kezarlifesciences.com.

Where are Kezar Life Sciences' headquarters?

Kezar Life Sciences is headquartered at 4000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Kezar Life Sciences?

Kezar Life Sciences' mailing address is 4000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-822-5600 or via email at [email protected]


This page was last updated on 3/8/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.